AstraZeneca Settles Nexium Kickback Suit; Deals Prohibiting Authorized Generic Sales Alleged
This article was originally published in The Pink Sheet Daily
AstraZeneca agreed to pay $7.9 million to resolve allegations it paid kickbacks to Medco Health Solutions for preferred formulary placement of Nexium.
You may also be interested in...
A look at the settlement agreements pharma companies have struck with the Department of Justice in the last three years; the size of the deals has declined dramatically since 2012.
Carl Reichel indicted for conspiring to pay kickbacks to physicians while firm pleads guilty to health care fraud; former DOJ attorneys provide insights on case.
Federal judge rules against Novartis’ motion to dismiss a whistleblower suit alleging violations of the anti-kickback statute and the False Claims Act, saying the government’s evidence is specific enough to proceed.